Literature DB >> 24007475

Defense mechanisms of the respiratory system and aerosol production systems.

Paul Zarogoulidis, Kaid Darwiche, Lonny Yarmus, Dionysios Spyratos, Nevena Secen, Wolfgang Hohenforst-Schmidt, Nikolaos Katsikogiannis, Haidong Huang, Andreas Gschwendtner, Konstantinos Zarogoulidis1.   

Abstract

Aerosolized therapies have been used in everyday clinical practice for decades. Experimentation with different delivery systems have led to the creation of aerosolized insulin, antibiotics, gene therapy and chemotherapy. Several of these therapies are already clinically available while others are being investigated in active clinical trials. The main factors affecting the efficiency and safety of the aerosolized therapies are the production of the aerosol, distribution/deposition of the aerosol throughout the lung parenchyma, respiratory defense mechanisms and tissue/pharmaceutical molecule interactions. Current methods of aerosol production and distribution will be presented along with an overview of the respiratory defense mechanisms. In addition, methods of aerosol evaluation in conjunction with a future perspective of the potential development of aerosol therapies will be presented.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24007475     DOI: 10.2174/157340641130900041

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  5 in total

1.  Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.

Authors:  Haidong Huang; Paul Zarogoulidis; Sofia Lampaki; John Organtzis; Dimitris Petridis; Konstantinos Porpodis; Antonis Papaiwannou; Vasilis Karageorgiou; Georgia Pitsiou; Ioannis Kioumis; Wolfgang Hohenforst-Schmidt; Qiang Li; Kaid Darwiche; Lutz Freitag; Aggeliki Rapti; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  DDMC-p53 gene therapy with or without cisplatin and microwave ablation.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Joshua Stopek; Thomas Vogl; Frank Hübner; J Francis Turner; Robert Browning; Konstantinos Zarogoulidis; Antonis Drevelegas; Konstantinos Drevelegas; Kaid Darwiche; Lutz Freitag; Harald Rittger
Journal:  Onco Targets Ther       Date:  2015-05-20       Impact factor: 4.147

3.  Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Dionysios Spyratos; Georgia Pitsiou; Dimitris Petridis; Athanasia Pataka; Haidong Huang; Qiang Li; Lonny Yarmus; Wolfgang Hohenforst-Schmidt; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-08-12       Impact factor: 4.162

4.  Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.

Authors:  Georgia Pitsiou; Paul Zarogoulidis; Dimitris Petridis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Antonis Papaiwannou; Theodora Tsiouda; Wolfgang Hohenforst-Schmidt; Stylianos Kakolyris; Konstantinos Syrigos; Haidong Huang; Qiang Li; J Francis Turner; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-10-07       Impact factor: 4.162

5.  Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Bernd Linsmeier; Ioannis Kioumis; Qiang Li; Haidong Huang; Despoina Sachpatzidou; Sofia Lampaki; John Organtzis; Kalliopi Domvri; Leonidas Sakkas; George A Zachariadis; Konstantinos N Archontas; Anastasios Kallianos; Aggeliki Rapti; Lonny Yarmus; Konstantinos Zarogoulidis; Johannes Brachmann
Journal:  J Cancer       Date:  2014-03-24       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.